多发性骨髓瘤相关的长非编码RNA PLUM通过增强PRC2介导的UPR通路激活来赋予化学抵抗
Kamalakshi Deka1, Jean-Michel Carter1, Akash Bahai1
1School of Biological Sciences (SBS), Nanyang Technological University (NTU), Singapore, Singapore.
Nature communications
|September 1, 2025
概括
一种新的长非编码RNA,PLUM,通过稳定PRC2复合体来驱动多发性骨髓瘤 (MM) 的化学抵抗. 针对PLUM-EZH2相互作用使耐火性MM细胞重新敏感.
科学领域:
- 血性恶性病
- 分子生物学
- 表观遗传学
背景情况:
- 多发性骨髓瘤 (MM) 是一种显著的血液恶性瘤,其特点是遗传异质性和耐治疗性.
- 在复发性/耐药性MM中,非正规NF-κB通路的过度激活是常见的,但化学抵抗机制尚不清楚.
- 了解耐药性驱动因素对于开发高风险MM患者有效治疗至关重要.
研究的目的:
- 确定多发性骨髓瘤中化学抵抗的新分子机制.
- 研究长非编码RNAs (lncRNAs) 在NF-κB突变,高风险MM中的作用.
- 探索针对已识别的抗药性途径的治疗策略.
主要方法:
- 在MM患者样本中识别和表征lncRNAPLUM.
- 研究PLUM与Polycomb Repressive Complex 2 (PRC2) 的相互作用及其对基因组甲基转移酶活性的影响.
- 评估PLUM在调节瘤抑制基因 (FOXO3,ZFP36) 和未折叠蛋白反应 (UPR) 的作用.
- 在体内使用固体抗意义寡核酸来破坏PLUM-EZH2相互作用并评估药物复敏性.
主要成果:
- 在NF-κB突变,高风险MM亚型和VRd耐药患者中,PLUM过度表达.
- 与PRC2相互作用,增强其稳定性和基因组甲基转移酶活性,从而导致表观遗传调节.
- 通过激活UPR和促进化学抵抗,
- 破坏PLUM- EZH2相互作用会使MM细胞对体内化疗重新敏感,从而降低PRC2稳定性和H3K27三甲基化.
结论:
- 通过促进PRC2复合体的形成和活性,PLUM是多发性骨髓瘤中化学抵抗的关键媒介.
- PLUM对瘤抑制基因的表观遗传调节和UPR的激活有助于治疗的折射性.
- 针对PLUM- EZH2相互作用是复发性和耐火性多发性骨髓瘤的有希望的治疗策略.
相关概念视频
lncRNA - Long Non-coding RNAs
8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Induced Pluripotent Stem Cells
4.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.4K


